Welcome to our dedicated page for Biolinerx news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Biolinerx stock.
BioLineRx Ltd (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company advancing innovative therapies in oncology and rare diseases, including its FDA-approved stem cell mobilizer APHEXDA®. This page provides centralized access to official company announcements, clinical trial updates, and strategic partnership developments.
Investors and researchers will find verified updates on pipeline progress, regulatory milestones, and operational initiatives. Content includes earnings reports, clinical data publications, licensing agreements, and manufacturing updates, all sourced directly from BioLineRx communications.
Regularly refreshed with new developments, this resource enables stakeholders to track the company’s work in areas like multiple myeloma treatment optimization and sickle cell disease gene therapy research. Bookmark this page for efficient monitoring of BLRX’s advancements in targeted drug development and commercialization strategies.
BioLineRx (NASDAQ: BLRX) has launched 'Mobilization Matters', a digital resource for multiple myeloma patients preparing for stem cell collection. The platform, launched on Apheresis Awareness Day, offers patient stories, educational resources, and a discussion guide to support patients undergoing this critical treatment phase.
In partnership with the HealthTree Foundation, BioLineRx is conducting the Mobilization Matters Stem Cell Collection Survey to gather patient insights about their experiences with stem cell collection and apheresis. Survey results are expected in Q1 2025. The initiative aims to enhance understanding and improve care strategies for multiple myeloma patients undergoing stem cell collection.
BioLineRx (NASDAQ: BLRX) reported its Q2 2024 financial results and recent updates. Key highlights include:
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures, surpassing Q2 goal
- Doubled the number of centers ordering APHEXDA during Q2
- Entered clinical trial agreement with St. Jude Children's Research Hospital for motixafortide in sickle cell disease
- Q2 revenue: $5.4 million, including $1.8 million from APHEXDA sales
- Net income: $0.5 million, compared to net loss of $18.5 million in Q2 2023
- Cash position: $40.1 million as of June 30, 2024, expected to fund operations into 2025
BioLineRx (NASDAQ: BLRX), a commercial stage biopharmaceutical company focusing on oncology and rare diseases, will announce its second quarter 2024 financial results on August 15, 2024, before the U.S. markets open.
The company will host a conference call at 8:30 a.m. EDT on the same day, featuring remarks by CEO Philip Serlin. Investors can join the call by dialing +1-888-281-1167 (U.S.) or +972-3-918-0685 (international).
A live webcast and replay of the call will be available on the company's website. The replay can also be accessed by dialing +1-888-295-2634 (U.S.) or +972-3-925-5904 (international) until August 19, 2024.
BioLineRx (NASDAQ: BLRX, TASE: BLRX) announced a Phase 1 clinical trial in collaboration with St. Jude Children's Research Hospital to evaluate motixafortide for mobilizing CD34+ hematopoietic stem cells (HSCs) in gene therapies for sickle cell disease (SCD). This study includes experts from St. Jude and two other clinical sites, focusing on new mobilization options due to the limitations of current strategies, like plerixafor, which require multiple cycles. Enrollment is set to start in a few months, and initial data from a related trial at Washington University is expected in late 2024. Motixafortide, BioLineRx's leading candidate, was FDA-approved in September 2023 for HSC mobilization in multiple myeloma patients.
BioLineRx (NASDAQ: BLRX) reported its Q1 2024 financial results and recent corporate updates. The company highlighted steady growth in APHEXDA® adoption, securing formulary placement at institutions representing ~26% of stem cell transplant procedures, targeting 35% by end of Q2. Key developments include new data presented at ASCO 2024 from a Phase 2b pancreatic cancer trial, and the approval of a motixafortide HSC mobilization study in China. Financials showed $6.9 million in total revenue and a net loss of $0.7 million, a significant improvement from a $12.2 million loss in Q1 2023. The company completed $26 million in debt and equity financing to support U.S. commercialization of APHEXDA.
BioLineRx (BLRX) announced new data from its Phase 2 CheMo4METPANC trial evaluating motixafortide in combination with cemiplimab and standard chemotherapies for first-line pancreatic cancer. The trial, presented at ASCO 2024, showed increased CD8+ T-cell density in tumors from all 11 patients. Of these, 64% experienced partial responses and 91% had disease control, surpassing historical rates of 23% and 48%, respectively. Preliminary median progression-free survival was 9.6 months, compared to 5.5 months historically. Based on these results, the trial has been expanded from 30 to 108 patients.
BioLineRx (NASDAQ: BLRX), a biopharmaceutical company focused on oncology and rare diseases, will release its unaudited first-quarter financial results for 2024 on May 28, 2024, before U.S. market hours. A conference call will be held at 8:30 a.m. EDT, hosted by CEO Philip Serlin. Access to the call is available via several international dial-ins, with a live webcast and replay accessible on the company's website. Dial-in replays will be available until May 30, 2024.
BioLineRx (NASDAQ: BLRX) has received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. This does not immediately affect the company's listing or trading on Nasdaq. BioLineRx has until November 11, 2024, to regain compliance by maintaining a bid price of at least $1.00 for 10 consecutive business days. If unsuccessful, an additional 180-day compliance period may be granted, provided other listing standards are met. The company's operations remain unaffected, and its shares continue to trade on the Tel Aviv Stock Exchange.
BioLineRx presented new economic model data for APHEXDA (motixafortide) for CD34+ hematopoietic stem cell mobilization in patients with multiple myeloma at the ISPOR 2024 conference. The data compared costs and healthcare resource utilization for patients undergoing autologous stem cell transplantation, highlighting potential benefits of using APHEXDA in reducing the need for multiple apheresis sessions.
FAQ
What is the current stock price of Biolinerx (BLRX)?
What is the market cap of Biolinerx (BLRX)?
